Keitaro Iida, Taku Naiki, Toshiki Etani, Takashi Nagai, Yosuke Sugiyama, Teruki Isobe, Maria Aoki, Satoshi Nozaki, Yusuke Noda, Nobuhiko Shimizu, Nami Tomiyama, Masakazu Gonda, Hiroyuki Kamiya, Hiroki Kubota, Akihiro Nakane, Ryosuke Ando, Noriyasu Kawai, Takahiro Yasui
We elucidated the efficacy of gut microbiome-altering drugs on pembrolizumab efficacy in patients with metastatic urothelial carcinoma (mUC). Clinical data were analyzed retrospectively from 133 patients with mUC who received second-line pembrolizumab therapy between January 2018 and January 2021, following failed platinum-based chemotherapy. We evaluated the effects of gut microbiome-altering drugs (proton pump inhibitors [PPI]/potassium-competitive acid blockers [P-CAB], H2 blockers, antibiotics, non-steroidal anti-inflammatory drugs [NSAIDs], metformin, antipsychotics, steroids, and opioids), taken by patients within 30 days before/after pembrolizumab treatment, on progression-free survival (PFS) and overall survival (OS)...
January 30, 2024: Scientific Reports